ArticleESMO open2017

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.

Jean-Jacques Grob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.